5'-Deoxy-5'-iodo-2'-O-methyl-5-methyluridine manufacturers
|
| | 5'-Deoxy-5'-iodo-2'-O-methyl-5-methyluridine Basic information |
| Product Name: | 5'-Deoxy-5'-iodo-2'-O-methyl-5-methyluridine | | Synonyms: | 5'-Deoxy-5'-iodo-2'-O-methyl-5-methyluridine;5’-Deoxy-5’-iodo-2’-O-methyl-5-methyuridine;Uridine, 5'-deoxy-5'-iodo-5-methyl-2'-O-methyl- (9CI);5'-deoxy-5'-iodo-5-methyl-2'-O-methyluridine;5’-Deoxy-5’-iodo-2’-O-methyl-5-methyluridine;1-((2R,3R,4S,5S)-4-Hydroxy-5-iodomethyl-3-methoxy-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione | | CAS: | 187733-72-8 | | MF: | C11H15IN2O5 | | MW: | 382.15 | | EINECS: | | | Product Categories: | | | Mol File: | 187733-72-8.mol |  |
| | 5'-Deoxy-5'-iodo-2'-O-methyl-5-methyluridine Chemical Properties |
| density | 1.84±0.1 g/cm3(Predicted) | | pka | 9.55±0.10(Predicted) |
| | 5'-Deoxy-5'-iodo-2'-O-methyl-5-methyluridine Usage And Synthesis |
| Uses | 5’-Deoxy-5’-iodo-2’-O-methyl-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1]. | | References | [1] Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88. DOI:10.2174/138161212801227005 |
| | 5'-Deoxy-5'-iodo-2'-O-methyl-5-methyluridine Preparation Products And Raw materials |
|